311 related articles for article (PubMed ID: 34077739)
1. Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib.
Dent P; Booth L; Poklepovic A; Von Hoff D; Martinez J; Zhou Y; Hancock JF
Biochem Pharmacol; 2021 Aug; 190():114642. PubMed ID: 34077739
[TBL] [Abstract][Full Text] [Related]
2. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.
Dent P; Booth L; Roberts JL; Liu J; Poklepovic A; Lalani AS; Tuveson D; Martinez J; Hancock JF
Oncogene; 2019 Jul; 38(30):5890-5904. PubMed ID: 31253872
[TBL] [Abstract][Full Text] [Related]
3. Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.
Dent P; Booth L; Poklepovic A; Martinez J; Hoff DV; Hancock JF
J Cell Physiol; 2020 Nov; 235(11):7889-7899. PubMed ID: 31912905
[TBL] [Abstract][Full Text] [Related]
4. Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells.
Booth L; Poklepovic A; Hancock JF; Dent P
Anticancer Drugs; 2023 Oct; 34(9):1025-1034. PubMed ID: 37703296
[TBL] [Abstract][Full Text] [Related]
5. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S
J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668
[TBL] [Abstract][Full Text] [Related]
6. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
[TBL] [Abstract][Full Text] [Related]
7. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
[TBL] [Abstract][Full Text] [Related]
8. Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFR
Xu J; Zhu GY; Cao D; Pan H; Li YW
Biomed Pharmacother; 2019 Jul; 115():108860. PubMed ID: 31055235
[TBL] [Abstract][Full Text] [Related]
9. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
Elife; 2021 Aug; 10():. PubMed ID: 34463254
[TBL] [Abstract][Full Text] [Related]
10. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
11. GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins.
Booth L; West C; Moore RP; Von Hoff D; Dent P
Front Oncol; 2021; 11():711043. PubMed ID: 34490108
[TBL] [Abstract][Full Text] [Related]
12. Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line.
Verusingam ND; Chen YC; Lin HF; Liu CY; Lee MC; Lu KH; Cheong SK; Han-Kiat Ong A; Chiou SH; Wang ML
J Chin Med Assoc; 2021 Mar; 84(3):248-254. PubMed ID: 33009209
[TBL] [Abstract][Full Text] [Related]
13. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC).
Bracht JWP; Karachaliou N; Berenguer J; Pedraz-Valdunciel C; Filipska M; Codony-Servat C; Codony-Servat J; Rosell R
Int J Biol Sci; 2019; 15(12):2607-2614. PubMed ID: 31754333
[TBL] [Abstract][Full Text] [Related]
15. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
Chen Z; Yu D; Owonikoko TK; Ramalingam SS; Sun SY
Oncogene; 2021 Dec; 40(49):6653-6665. PubMed ID: 34635799
[TBL] [Abstract][Full Text] [Related]
16. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
[TBL] [Abstract][Full Text] [Related]
17.
Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T
Mol Cancer Ther; 2019 Jan; 18(1):112-126. PubMed ID: 30322949
[TBL] [Abstract][Full Text] [Related]
18. Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation.
Oku Y; Nishiya N; Sugiyama S; Sato H; Uehara Y
Anticancer Res; 2018 Jun; 38(6):3471-3476. PubMed ID: 29848699
[TBL] [Abstract][Full Text] [Related]
19. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
20. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]